GlassScriptPhysician profile
Lotika Singh
NPI 1023342748
$12,107.35
in general payments reported to CMS, 2019-2025
29 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $687 · 2021: $788 · 2022: $1,727 · 2023: $2,225 · 2024: $3,064 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,171 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.73 |
| Education | $458.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,689.64 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $1,002.47 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $957.39 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $898.81 | 2019-2025 | Rinvoq, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $865.37 | 2019-2025 | |
| Pfizer INC. | $721.23 | 2019-2025 | |
| Janssen Biotech, INC. | $677.55 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $668.53 | 2019-2025 | |
| Galderma Laboratories, L.P. | $638.59 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $564.49 | 2023-2024 | Vtama |
| Incyte Corporation | $427.12 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $420.51 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $411.39 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $397.59 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $389.58 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $312.20 | 2025 | Sofdra |
| Celgene Corporation | $265.71 | 2019 | |
| Almirall LLC | $234.88 | 2019-2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.84 | 2019-2025 | Arazlo, Duobrii, Cabtreo |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Mayne Pharma Commercial LLC | $62.21 | 2019-2021 | |
| Ucb, INC. | $56.72 | 2021-2025 | Bimzelx |
| Organon LLC | $45.54 | 2025 | Vtama |
| Dermira, INC. | $44.53 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $39.46 | 2021 | |
| Endo Pharmaceuticals INC. | $29.50 | 2020 | |
| Medimetriks Pharmaceuticals, INC. | $24.45 | 2019 | |
| Encore Dermatology INC. | $22.94 | 2020 | |
| Journey Medical Corporation | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lotika Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.